Fleury, H.; Caldato, S.; Recordon-Pinson, P.; Thebault, P.; Guidicelli, G.-L.; Hessamfar, M.; Morlat, P.; Bonnet, F.; Visentin, J.
ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study). Viruses 2020, 12, 1256.
https://doi.org/10.3390/v12111256
AMA Style
Fleury H, Caldato S, Recordon-Pinson P, Thebault P, Guidicelli G-L, Hessamfar M, Morlat P, Bonnet F, Visentin J.
ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study). Viruses. 2020; 12(11):1256.
https://doi.org/10.3390/v12111256
Chicago/Turabian Style
Fleury, Hervé, Sabrina Caldato, Patricia Recordon-Pinson, Patricia Thebault, Gwenda-Line Guidicelli, Mojgan Hessamfar, Philippe Morlat, Fabrice Bonnet, and Jonathan Visentin.
2020. "ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study)" Viruses 12, no. 11: 1256.
https://doi.org/10.3390/v12111256
APA Style
Fleury, H., Caldato, S., Recordon-Pinson, P., Thebault, P., Guidicelli, G.-L., Hessamfar, M., Morlat, P., Bonnet, F., & Visentin, J.
(2020). ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study). Viruses, 12(11), 1256.
https://doi.org/10.3390/v12111256
